In an older adult with bilateral subpleural reticulations indicating stable fibrotic lung disease and a 13 mm hypodense nodule in the right thyroid lobe (thyroid assessment limited by metallic artifact), what surveillance and specialist referral recommendations are appropriate for the lung findings and the thyroid nodule?

Management of Bilateral Subpleural Reticulations and Thyroid Nodule

This patient requires referral to a pulmonologist for evaluation of stable fibrotic interstitial lung disease and ultrasound evaluation of the thyroid nodule with potential biopsy based on sonographic features.

Pulmonary Findings: Bilateral Subpleural Reticulations

Immediate Actions

Refer to a pulmonologist or expert center for comprehensive evaluation. 1 The presence of bilateral subpleural reticulations indicating fibrotic changes requires multidisciplinary assessment combining radiologic, clinical, and functional data to determine if this represents progressive pulmonary fibrosis (PPF) or stable interstitial lung abnormalities (ILA). 1

Risk Stratification and Surveillance

• The stability noted on prior imaging is reassuring but does not eliminate the need for monitoring. 2 Subpleural reticulations, even when initially stable, carry a 43.6% risk of radiological progression over 4 years, with reticulation itself being an independent predictor of progression (odds ratio 1.9). 2

• High-resolution CT (HRCT) with thin sections (1.5 mm) should be performed for detailed assessment if not already done. 1 The current CT was of the neck/thyroid and may not have optimal lung imaging parameters for fibrosis quantification.

• Follow-up HRCT timing should be determined by the pulmonologist based on clinical context, but typically ranges from 12-24 months for stable-appearing fibrotic changes. 1 The 2025 Italian consensus recommends side-by-side comparison of serial HRCTs to assess for progression features including: increased extent of reticulation, new or increased traction bronchiectasis, new ground-glass opacities with traction bronchiectasis, new honeycombing, or increased lobar volume loss. 1

Clinical Evaluation Components

The pulmonologist should assess for:

• Respiratory symptoms (dyspnea, cough) even if subtle, as sedentary patients may not report limitations 1
• Pulmonary function tests including spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO), as DLCO is often the earliest physiologic abnormality 1
• Oxygen saturation at rest and with exertion 1
• Risk factors including smoking history, occupational/environmental exposures, connective tissue disease symptoms, family history of ILD, and genetic predispositions 3, 4

Prognostic Considerations

The presence of subpleural reticulations, even without definite traction bronchiectasis or honeycombing, warrants close attention. 1, 2 While the current findings may represent interstitial lung abnormalities (ILA) rather than definite interstitial lung disease (ILD), the distinction is critical as ILA with fibrotic features carries hazard ratios for mortality ranging from 1.3 to 2.7 in large cohorts. 3

Thyroid Nodule: 13 mm Hypodense Right Lobe Nodule

Immediate Actions

Obtain thyroid ultrasound as the next step. 1 CT cannot reliably differentiate benign from malignant thyroid nodules unless there is gross invasion or metastatic disease. 1 Ultrasound provides high-resolution characterization and allows risk stratification using ACR TI-RADS or similar systems. 1

Ultrasound-Based Management Algorithm

• If ultrasound confirms a 13 mm nodule with suspicious features (hypoechogenicity, irregular margins, microcalcifications, taller-than-wide shape, increased vascularity), fine-needle aspiration biopsy is indicated. 5, 6

• If ultrasound shows benign features (spongiform appearance, pure cyst, or entirely calcified), surveillance may be appropriate based on ACR TI-RADS scoring. 1, 5

• The stability mentioned in the CT report is helpful but does not replace ultrasound evaluation, as ultrasound is superior for characterizing nodule features predictive of malignancy. 1

Thyroid Function Testing

Check serum TSH before proceeding with further evaluation. 1 If TSH is subnormal, the patient has thyrotoxicosis and management differs (radionuclide scanning may be indicated). 1

Surveillance Considerations

• For benign-appearing nodules on ultrasound, follow-up intervals depend on size and TI-RADS category, typically ranging from 1-5 years or no follow-up for very low-risk nodules. 5, 6

• The incidental nature of this finding (detected on CT) is common, with true prevalence of thyroid nodules on CT imaging estimated at 11.8% in screening populations. 7 However, the 13 mm size exceeds most thresholds for requiring workup (typically 10-20 mm depending on guidelines). 7

Malignancy Risk Context

The malignancy rate for incidentally detected thyroid nodules on CT is approximately 0.1%, but this increases with nodule size and suspicious ultrasound features. 7 The hypodense appearance on CT is nonspecific and requires ultrasound correlation. 1

Integration and Pitfalls

Common pitfall: Assuming CT stability of the thyroid nodule eliminates the need for ultrasound. CT lacks the resolution to adequately characterize thyroid nodules for malignancy risk. 1

Common pitfall: Dismissing stable-appearing lung reticulations as clinically insignificant. Even stable subpleural reticulations require specialist evaluation to determine progression risk and establish baseline for future comparison. 1, 2

The metallic artifact from the left shoulder arthroplasty limits complete thyroid evaluation on CT, making ultrasound even more essential for comprehensive assessment. 1